Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Five Prime Therapeutics Inc.

www.fiveprime.com

Latest From Five Prime Therapeutics Inc.

Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks

Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.

Financing StartUps and SMEs

Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy

Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.

Business Strategies Deals

Asia's Nasdaq? Hong Kong‘s Quest To Be IPO Power House Has Blessings And Curses

Hundreds of executives showed up at an inaugural biotech summit organized by the Hong Kong Stock Exchange, setting the stage for a showdown between the territory and the most popular destination for biotech IPOs, Nasdaq in the US. Despite recent rule changes to allow pre-revenue biotechs to gain a listing more easily, executives still see hurdles that are associated with Hong Kong's close proximity to the very market it is trying to allure, mainland China.

Financing Hong Kong

Appointments: Roche, Eli Lilly, Ipsen And Syros Make New Leadership Hires, Plus Board Appointments At EUSA, Autolus And Forendo

The latest biopharma industry personnel moves include a new executive hires at Roche, Lilly Oncology, Ipsen and Syros, a resignation at Five Prime, plus new board appointments at EUSA, Autolus and Forendo. 

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • FivePrime Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Five Prime Therapeutics Inc.
  • Senior Management
  • Aron Knickerbocker, MD, PhD, CEO
    Francis Sarena, Chief Strategy Officer and Secretary
    Helen Collins, MD, SVP, CMO
  • Contact Info
  • Five Prime Therapeutics Inc.
    Phone: (415) 365-5600
    111 Oyster Point Blvd.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register